Molecular Oncology of Gastrointestinal Tumors

Scientific Background

  • Study Biology, Leiden University, The Netherlands
  • PhD student, Dept. for Molecular Carcinogenesis (Prof. Dr. A.J. van der Eb), Leiden University, The Netherlands & Forschungszentrum Karlsruhe, Institut für Genetik (Prof. Dr. P. Herrlich), Karlsruhe, Germany
  • Postdoctoral research fellow, Div. Pediatric Oncology (Prof. Dr. S.J. Burakoff), Dana Farber Cancer Institute, Boston, USA
  • Head Tumor Immunology Group, Dept. of Immunohematology & Blood transfusion, Leiden University Medical Center, Leiden, The Netherlands
  • Principal Scientist, Immunology Discovery, Genentech Inc., South San Francisco, USA
  • Head of the Div. of Molecular Oncology of Gastrointestinal Cancers, German Cancer Research Center (DKFZ)
  • Head of the Div. of Pancreas Carcinoma Research, Surgery Clinic of Heidelberg University

Consultancies

  • Consultant to Cantab/Xenova Pharmaceuticals, Cambridge, U.K.(1999 – 2001)
  • Consultant to Zycos Inc., Boston, USA (2001)
  • Member scientific advisory board Accuro, Stockholm, Sweden (2000 – 2003)
  • Consultant to Medigene, Munich, Germany (2002)
  • Consultant to Innogenetics, Gent, Belgium (2004)
  • Consultant to Glaxo Smith Kline (GSK) (2005)
  • Member Strategy Team ISA Pharmaceuticals, Leiden The Netherlands (2005-2007)
  • Member scientific advisory board Transgene, Strasbourg, France (2006 - 2007)
  • Chairman of the LSBR (Landsteiner Foundation of Blood Transfusion Research) Scientific Advisory Council (2004-2007)
  • Associate Editor Cancer Research (2007-2010)
  • Associate Editor The Journal of Immunology
  • Member Editorial Board for the International Society for Biological Therapy of Cancer (iSBTc) Journal of Translational Medicine.
  • Member of Faculty of 1000

Publications

Publications

  1. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A. 2011. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19: 101-13
  2. Burington B, Yue P, Shi X, French D, Polson AG, Offringa R, Whiting N, Ebens A, Dornan D. 2011. CD40 pathway activation status predicts the anti-tumor activity of CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med in press
  3. van den Hende M, Redeker A, Kwappenberg KM, Franken KL, Drijfhout JW, Oostendorp J, Valentijn AR, Fathers LM, Welters MJ, Melief CJ, Kenter GG, van der Burg SH, Offringa R. 2010. Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses. J Infect Dis 202: 1200-11
  4. Oliveira CC, van Veelen PA, Querido B, de Ru A, Sluijter M, Laban S, Drijfhout JW, van der Burg SH, Offringa R, van Hall T. 2010. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med 207: 207-21
  5. Fransen MF, van Stipdonk MJ, Sluijter M, Schoenberger SP, Melief CJ, Offringa R. 2010. Separate roles for antigen recognition and lymph node inflammation in CD8+ memory T cell formation. J Immunol 185: 3167-73
  6. van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, van Hall T, Achour A. 2009. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res 69: 7784-92
  7. Offringa R. 2009. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol 21: 190-9
  8. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361: 1838-47
  9. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH. 2008. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14: 178-87
  10. van Stipdonk MJ, Sluijter M, Han WG, Offringa R. 2008. Development of CTL memory despite arrested clonal expansion. Eur J Immunol 38: 1839-46
  11. van den Hende M, van Poelgeest MI, van der Hulst JM, de Jong J, Drijfhout JW, Fleuren GJ, Valentijn AR, Wafelman AR, Slappendel GM, Melief CJ, Offringa R, van der Burg SH, Kenter GG. 2008. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. Int J Cancer 123: 146-52
  12. Speetjens FM, Lauwen MM, Franken KL, Janssen-van Rhijn CM, van Duikeren S, Bres SA, van de Velde CJ, Melief CJ, Kuppen PJ, van der Burg SH, Morreau H, Offringa R. 2008. Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer 123: 838-45
  13. Roelen DL, van den Boogaardt DE, van Miert PP, Koekkoek K, Offringa R, Claas FH. 2008. Differentially modulated dendritic cells induce regulatory T cells with different characteristics. Transpl Immunol 19: 220-8
  14. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren GJ, Kenter GG, Offringa R, van der Burg SH. 2008. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 122: 486-94
  15. Lauwen MM, Zwaveling S, de Quartel L, Ferreira Mota SC, Grashorn JA, Melief CJ, van der Burg SH, Offringa R. 2008. Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. Cancer Res 68: 893-900
  16. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ. 2008. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14: 169-77
  17. Dierssen JW, van Puijenbroek M, Dezentje DA, Fleuren GJ, Cornelisse CJ, van Wezel T, Offringa R, Morreau H. 2008. Frequent mutations in the 3'-untranslated region of IFNGR1 lack functional impairment in microsatellite-unstable colorectal tumours. Eur J Hum Genet 16: 1235-9
  18. Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TN, Haanen JB, van der Burg SH, Melief CJ, Offringa R. 2008. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 68: 8446-55
  19. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. 2008. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 38: 1033-42
  20. Welters MJ, Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. 2007. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 25: 1379-89
  21. van Hall T, Laban S, Koppers-Lalic D, Koch J, Precup C, Asmawidjaja P, Offringa R, Wiertz EJ. 2007. The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1. J Immunol 178: 657-62
  22. van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R. 2007. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 104: 12087-92
  23. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. 2007. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67: 354-61
  24. Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H. 2007. P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int J Cancer 121: 606-14
  25. Chambers B, Grufman P, Fredriksson V, Andersson K, Roseboom M, Laban S, Camps M, Wolpert EZ, Wiertz EJ, Offringa R, Ljunggren HG, van Hall T. 2007. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Cancer Res 67: 8450-5
  26. Bos R, van Duikeren S, van Hall T, Lauwen MM, Parrington M, Berinstein NL, McNeil B, Melief CJ, Verbeek JS, van der Burg SH, Offringa R. 2007. Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J Immunol 179: 6115-22
  27. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. 2007. CD8+ CTL priming by exact peptide epitopes in incomplete freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179: 5033-40
  28. Bijker MS, Melief CJ, Offringa R, van der Burg SH. 2007. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 6: 591-603
  29. Welters MJ, van der Logt P, van den Eeden SJ, Kwappenberg KM, Drijfhout JW, Fleuren GJ, Kenter GG, Melief CJ, van der Burg SH, Offringa R. 2006. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 118: 950-6
  30. van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH. 2006. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 118: 675-83
  31. van Hall T, Wolpert EZ, van Veelen P, Laban S, van der Veer M, Roseboom M, Bres S, Grufman P, de Ru A, Meiring H, de Jong A, Franken K, Teixeira A, Valentijn R, Drijfhout JW, Koning F, Camps M, Ossendorp F, Karre K, Ljunggren HG, Melief CJ, Offringa R. 2006. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12: 417-24
  32. van der Burg SH, Bijker MS, Welters MJ, Offringa R, Melief CJ. 2006. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev 58: 916-30
  33. Offringa R. 2006. Cancer. Cancer immunotherapy is more than a numbers game. Science 314: 68-9
  34. Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC, Ossendorp F, Melief CJ. 2006. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 20: 1738-50
  35. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. 2006. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 90: 175-213
  36. Bots M, L VANB, Rademaker MT, Offringa R, Medema JP. 2006. Serpins prevent granzyme-induced death in a species-specific manner. Immunol Cell Biol 84: 79-86
  37. Bots M, Offringa R, Medema JP. 2006. Does the serpin PI-9 protect tumor cells? Blood 107: 4974-5; author reply 5
  38. van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH. 2005. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 11: 5273-80
  39. Smakman N, Veenendaal LM, van Diest P, Bos R, Offringa R, Borel Rinkes IH, Kranenburg O. 2005. Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. Oncogene
  40. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn CM, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ. 2005. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 11: 2576-82
  41. Offringa R, Kwappenberg K, Rabelink M, Rea D, Hoeben R. 2005. Adenoviral transduction of dendritic cells. Methods Mol Med 109: 83-96
  42. Offringa R. 2005. Tumour immunology exploitation of the weapon of immune destruction for cancer therapy: taking aim before firing. Curr Opin Immunol 17: 159-62
  43. Fournel S, Wieckowski S, Sun W, Trouche N, Dumortier H, Bianco A, Chaloin O, Habib M, Peter JC, Schneider P, Vray B, Toes RE, Offringa R, Melief CJ, Hoebeke J, Guichard G. 2005. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol 1: 377-82
  44. Dumortier H, van Mierlo GJ, Egan D, van Ewijk W, Toes RE, Offringa R, Melief CJ. 2005. Antigen Presentation by an Immature Myeloid Dendritic Cell Line Does Not Cause CTL Deletion In Vivo, but Generates CD8+ Central Memory-Like T Cells That Can Be Rescued for Full Effector Function. J Immunol 175: 855-63
  45. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. 2005. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. Cancer Res 65: 6984-9
  46. de Jong A, van der Hulst JM, Kenter GG, Drijfhout JW, Franken KL, Vermeij P, Offringa R, van der Burg SH, Melief CJ. 2005. Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer 114: 274-82
  47. Bots M, Kolfschoten IG, Bres SA, Rademaker MT, de Roo GM, Kruse M, Franken KL, Hahne M, Froelich CJ, Melief CJ, Offringa R, Medema JP. 2005. SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. Blood 105: 1153-61
  48. Bos R, van Duikeren S, van Hall T, Kaaijk P, Taubert R, Kyewski B, Klein L, Melief CJ, Offringa R. 2005. Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 65: 6443-9
  49. Welters MJ, Filippov DV, van den Eeden SJ, Franken KL, Nouta J, Valentijn AR, van der Marel GA, Overkleeft HS, Lipford G, Offringa R, Melief CJ, van Boom JH, van der Burg SH, Drijfhout JW. 2004. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine 23: 305-11
  50. van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ. 2004. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 173: 6753-9
  51. Sutmuller RP, Offringa R, Melief CJ. 2004. Revival of the regulatory T cell: new targets for drug development. Drug Discov Today 9: 310-6
  52. Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH. 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 10: 2954-61
  53. Rea D, Laface D, Hutchins B, Kwappenberg K, Melief CJ, Hoeben RC, Offringa R. 2004. Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cells. Hum Immunol 65: 1344-55
  54. Hofmann M, Radsak M, Rechtsteiner G, Wiemann K, Gunder M, Bien-Grater U, Offringa R, Toes RE, Rammensee HG, Schild H. 2004. T cell avidity determines the level of CTL activation. Eur J Immunol 34: 1798-806
  55. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. 2004. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol 172: 6074-9
  56. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH. 2004. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64: 5449-55
  57. Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn C, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ. 2004. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother 53: 978-86
  58. Boonman ZF, van Mierlo GJ, Fransen MF, Franken KL, Offringa R, Melief CJ, Jager MJ, Toes RE. 2004. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. J Immunol 172: 1567-74
  59. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. 2003. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 101: 1439-45
  60. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH. 2003. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63: 636-41
  61. Van der Burg SH, Menon AG, Redeker A, Melief CJ, Offringa R. 2003. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. Int J Cancer 107: 425-31
  62. Theobald M, Offringa R. 2003. Anti-p53-directed immunotherapy of malignant disease. Expert Rev Mol Med 2003: 1-13
  63. Roelen DL, Schuurhuis DH, van den Boogaardt DE, Koekkoek K, van Miert PP, van Schip JJ, Laban S, Rea D, Melief CJ, Offringa R, Ossendorp F, Claas FH. 2003. Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. Transplantation 76: 1608-15
  64. Ossevoort M, Visser BM, van den Wollenberg DJ, van der Voort EI, Offringa R, Melief CJ, Toes RE, Hoeben RC. 2003. Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther 10: 2020-8
  65. Offringa R, de Jong A, Toes RE, van der Burg SH, Melief CJ. 2003. Interplay between human papillomaviruses and dendritic cells. Curr Top Microbiol Immunol 276: 215-40
  66. Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, Snijders A, Offringa R, de Vries RR, Toes RE. 2003. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 48: 1452-60
  67. Menon AG, Kuppen PJ, van der Burg SH, Offringa R, Bonnet MC, Harinck BI, Tollenaar RA, Redeker A, Putter H, Moingeon P, Morreau H, Melief CJ, van de Velde CJ. 2003. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 10: 509-17
  68. Kessler JH, Mommaas B, Mutis T, Huijbers I, Vissers D, Benckhuijsen WE, Schreuder GM, Offringa R, Goulmy E, Melief CJ, van der Burg SH, Drijfhout JW. 2003. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum Immunol 64: 245-55
  69. Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC. 2003. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 9: 5205-13
  70. Zwaveling S, Van der Burg SH, Menon AG, Melief CJ, Offringa R. 2002. Immunotherapy of cancer through targeting of the p53 tumor antigen. Arch Immunol Ther Exp (Warsz) 50: 297-305
  71. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ. 2002. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 62: 6187-93
  72. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169: 350-8
  73. Wiegant J, van Hall T, van der Burg M, Colombo M, Tanke HJ, Offringa R, Rosenberg C. 2002. Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. Cancer Genet Cytogenet 139: 126-32
  74. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE. 2002. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A 99: 5561-6
  75. van der Burg SH, de Jong A, Welters MJ, Offringa R, Melief CJ. 2002. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res 89: 275-84
  76. van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ. 2002. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 8: 1019-27
  77. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R. 2002. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188: 177-82
  78. Heukamp LC, van Hall T, Ossendorp F, Burchell JM, Melief CJ, Taylor-Papadimitriou J, Offringa R. 2002. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 25: 46-56
  79. Diehl L, van Mierlo GJ, den Boer AT, van der Voort E, Fransen M, van Bostelen L, Krimpenfort P, Melief CJ, Mittler R, Toes RE, Offringa R. 2002. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol 168: 3755-62
  80. de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR, Dobson JA, Jack LC, St Clair Roberts JA, Offringa R, van der Burg SH, Hickling JK. 2002. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20: 3456-64
  81. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R. 2002. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62: 472-9
  82. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194: 481-9.
  83. van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, Offringa R. 2001. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19: 3652-60.
  84. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R. 2001. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91: 612-8.
  85. van der Burg SH, de Cock K, Menon AG, Franken KL, Palmen M, Redeker A, Drijfhout J, Kuppen PJ, van de Velde C, Erdile L, Tollenaar RA, Melief CJ, Offringa R. 2001. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 31: 146-55.
  86. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: 823-32.
  87. Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R. 2001. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 166: 5236-44.
  88. Rea D, Johnson ME, Havenga MJ, Melief CJ, Offringa R. 2001. Strategies for improved antigen delivery into dendritic cells. Trends Mol Med 7: 91-4.
  89. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R. 2001. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98: 11515-20.
  90. Medema JP, Schuurhuis DH, Rea D, van Tongeren J, de Jong J, Bres SA, Laban S, Toes RE, Toebes M, Schumacher TN, Bladergroen BA, Ossendorp F, Kummer JA, Melief CJ, Offringa R. 2001. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 194: 657-67.
  91. Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. 2001. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 193: 73-88.
  92. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R. 2001. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 91: 385-92.
  93. Heinzel S, Rea D, Offringa R, Pawelec G. 2001. The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells. Cancer Immunol Immunother 49: 671-8.
  94. den Boer AT, Diehl L, van Mierlo GJ, van der Voort EI, Fransen MF, Krimpenfort P, Melief CJ, Offringa R, Toes RE. 2001. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol 167: 2522-8.
  95. Vierboom MP, Zwaveling S, Bos GMJ, Ooms M, Krietemeijer GM, Melief CJ, Offringa R. 2000. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 60: 5508-13.
  96. Vierboom MP, Bos GM, Ooms M, Offringa R, Melief CJ. 2000. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer 87: 253-60.
  97. van Hall T, Sijts A, Camps M, Offringa R, Melief C, Kloetzel PM, Ossendorp F. 2000. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J Exp Med 192: 483-94.
  98. van Hall T, van Bergen J, van Veelen PA, Kraakman M, Heukamp LC, Koning F, Melief CJ, Ossendorp F, Offringa R. 2000. Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin. J Immunol 165: 869-77.
  99. van Bergen J, Camps M, Offringa R, Melief CJ, Ossendorp F, Koning F. 2000. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide. Cancer Res 60: 6427-33.
  100. Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R. 2000. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. J Immunol 165: 7308-15.
  101. Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EI, Rea D, Offringa R, Geuze HJ, Melief CJ, Ossendorp F. 2000. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 192: 145-50.
  102. Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ. 2000. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60: 6995-7001.
  103. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Melief CJ. 2000. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23: 255-66
  104. Rea D, van Kooten C, van Meijgaarden KE, Ottenhoff TH, Melief CJ, Offringa R. 2000. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 95: 3162-7.
  105. Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. 2000. Importance of CD4(+) T helper cell responses in tumor immunity. Immunol Lett 74: 75-9.
  106. Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ. 2000. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr Opin Immunol 12: 576-82.
  107. Offringa R, Vierboom MP, van der Burg SH, Erdile L, Melief CJ. 2000. p53: a potential target antigen for immunotherapy of cancer. Ann N Y Acad Sci 910: 223-33; discussion 33-6.
  108. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. 2000. Strategies for immunotherapy of cancer. Adv Immunol 75: 235-82
  109. Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE. 2000. The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med 78: 363-71
  110. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJ, Trimbos JB. 1999. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35: 946-52.
  111. van der Burg SH, Kwappenberg KM, Geluk A, van der Kruk M, Pontesilli O, Hovenkamp E, Franken KL, van Meijgaarden KE, Drijfhout JW, Ottenhoff TH, Melief CJ, Offringa R. 1999. Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. J Immunol 162: 152-60.
  112. Toes RE, Ossendorp F, Offringa R, Melief CJ. 1999. CD4 T cells and their role in antitumor immune responses. J Exp Med 189: 753-6.
  113. Ressing ME, de Jong JH, Brandt RM, Drijfhout JW, Benckhuijsen WE, Schreuder GM, Offringa R, Kast WM, Melief CJ. 1999. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol 29: 1292-303.
  114. Rea D, Schagen FH, Hoeben RC, Mehtali M, Havenga MJ, Toes RE, Melief CJ, Offringa R. 1999. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 73: 10245-53.
  115. Melief CJ, Schoenberger S, Toes R, Offringa R. 1999. Cytotoxic T lymphocyte priming versus cytotoxic T lymphocyte tolerance induction: a delicate balancing act involving dendritic cells. Haematologica 84 Suppl EHA-4: 26-7.
  116. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190: 1033-8.
  117. Irvine KR, Parkhurst MR, Shulman EP, Tupesis JP, Custer M, Touloukian CE, Robbins PF, Yafal AG, Greenhalgh P, Sutmuller RP, Offringa R, Rosenberg SA, Restifo NP. 1999. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res 59: 2536-40.
  118. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5: 774-9.
  119. van Hall T, van de Rhee NE, Schoenberger SP, Vierboom MP, Verreck FA, Melief CJ, Offringa R. 1998. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res 58: 3087-93.
  120. Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. 1998. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 10: 443-8.
  121. Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJ. 1998. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 160: 4449-56.
  122. Schoenberger SP, van der Voort EI, Krietemeijer GM, Offringa R, Melief CJ, Toes RE. 1998. Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells. J Immunol 161: 3808-12.
  123. Schoenberger SP, Jonges LE, Mooijaart RJ, Hartgers F, Toes RE, Kast WM, Melief CJ, Offringa R. 1998. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res 58: 3094-100.
  124. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-3.
  125. Pawelec G, Mariani E, Offringa R, Melief CJM, Solana R. 1998. Generation and characterization of killer cells. Methods in Microbiol 25: 605-19
  126. Nieland JD, Haks MC, Kremers BL, Leupers TJ, Bakker AQ, Offringa R, Kruisbeek AM. 1998. Functional analysis of Ran/TC4 as a protein regulating T-cell costimulation. Cancer Gene Ther 5: 259-73.
  127. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, Reinhardus C, Shabanowitz J, Offringa R, Hunt DF, Engelhard VH, Goulmy E. 1998. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279: 1054-7.
  128. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, Melief CJ. 1998. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 58: 724-31.
  129. Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186: 695-704.
  130. van der Burg SH, Visseren MJ, Offringa R, Melief CJ. 1997. Do epitopes derived from autoantigens display low affinity for MHC class I? Immunol Today 18: 97-8.
  131. van Bergen J, Schoenberger SP, Verreck F, Amons R, Offringa R, Koning F. 1997. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci U S A 94: 7499-502.
  132. Toes RE, Hoeben RC, van der Voort EI, Ressing ME, van der Eb AJ, Melief CJ, Offringa R. 1997. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci U S A 94: 14660-5.
  133. Toes RE, Schoenberger SP, van der Voort EI, Kast WM, Hoeben RC, Melief CJ, Offringa R. 1997. Activation or frustration of anti-tumor responses by T-cell-based immune modulation. Semin Immunol 9: 323-7.
  134. Ras E, van der Burg SH, Zegveld ST, Brandt RM, Kuppen PJ, Offringa R, Warnarr SO, van de Velde CJ, Melief CJ. 1997. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol 53: 81-9.
  135. Medema JP, Toes RE, Scaffidi C, Zheng TS, Flavell RA, Melief CJ, Peter ME, Offringa R, Krammer PH. 1997. Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur J Immunol 27: 3492-8.
  136. Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. 1996. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 56: 3782-7.
  137. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 93: 7855-60.
  138. Toes RE, Kast WM, Blom RJ, Bakker SC, Offringa R, Melief CJ. 1996. Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts. Int J Cancer 66: 686-91.
  139. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. 1996. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 156: 3911-8.
  140. Ressing ME, Offringa R, Toes RE, Ossendorp F, de Jong JH, Brandt RM, Kast WM, Melief CJ. 1996. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology 2: 241-51.
  141. Melief CJ, Offringa R, Toes RE, Kast WM. 1996. Peptide-based cancer vaccines. Curr Opin Immunol 8: 651-7.
  142. Wieles B, Spierings E, van Noort J, Naafs B, Offringa R, Ottenhoff T. 1995. Molecular characterization and T-cell-stimulatory capacity of Mycobacterium leprae antigen T5. Infect Immun 63: 4682-5.
  143. Wieles B, van Noort J, Drijfhout JW, Offringa R, Holmgren A, Ottenhoff TH. 1995. Purification and functional analysis of the Mycobacterium leprae thioredoxin/thioredoxin reductase hybrid protein. J Biol Chem 270: 25604-6.
  144. Wieles B, van Soolingen D, Holmgren A, Offringa R, Ottenhoff T, Thole J. 1995. Unique gene organization of thioredoxin and thioredoxin reductase in Mycobacterium leprae. Mol Microbiol 16: 921-9.
  145. Toes RE, Feltkamp MC, Ressing ME, Vierboom MP, Blom RJ, Brandt RM, Hartman M, Offringa R, Melief CJ, Kast WM. 1995. Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. Biochem Soc Trans 23: 692-6.
  146. Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. 1995. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol 154: 3396-405.
  147. Toes RE, Offringa R, Feltkamp MC, Visseren MJ, Schoenberger SP, Melief CJ, Kast WM. 1994. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst Mitt: 72-86.
  148. Schmidt ED, Cramer SJ, Offringa R. 1993. The thyroid hormone receptor interferes with transcriptional activation via the AP-1 complex. Biochem Biophys Res Commun 192: 151-60.
  149. Offringa R, Bierer BE. 1993. Association of CD2 with tubulin. Evidence for a role of the cytoskeleton in T cell activation. J Biol Chem 268: 4979-88.
  150. Hagmeyer BM, Konig H, Herr I, Offringa R, Zantema A, van der Eb A, Herrlich P, Angel P. 1993. Adenovirus E1A negatively and positively modulates transcription of AP-1 dependent genes by dimer-specific regulation of the DNA binding and transactivation activities of Jun. Embo J 12: 3559-72.
  151. Lowik CW, Hoekman K, Offringa R, Groot CG, Hendy GN, Papapoulos SE, Ponec M. 1992. Regulation of parathyroid hormonelike protein production in cultured normal and malignant keratinocytes. J Invest Dermatol 98: 198-203.
  152. van Dam H, Offringa R, Meijer I, Stein B, Smits AM, Herrlich P, Bos JL, van der Eb AJ. 1990. Differential effects of the adenovirus E1A oncogene on members of the AP-1 transcription factor family. Mol Cell Biol 10: 5857-64.
  153. Offringa R, Gebel S, van Dam H, Timmers M, Smits A, Zwart R, Stein B, Bos JL, van der Eb A, Herrlich P. 1990. A novel function of the transforming domain of E1a: repression of AP-1 activity. Cell 62: 527-38.
  154. van der Eb AJ, Timmers HT, Offringa R, Zantema A, van den Heuvel SJ, van Dam JA, Bos JL. 1989. Suppression of cellular gene activity in adenovirus-transformed cells. Curr Top Microbiol Immunol 144: 197-207
  155. van Dam H, Offringa R, Smits AM, Bos JL, Jones NC, van der Eb AJ. 1989. The repression of the growth factor-inducible genes JE, c-myc and stromelysin by adenovirus E1A is mediated by conserved region 1. Oncogene 4: 1207-12.
  156. Melief CJ, Vasmel WL, Offringa R, Sijts EJ, Matthews EA, Peters PJ, Meloen RH, van der Eb AJ, Kast WM. 1989. Immunosurveillance of virus-induced tumors. Cold Spring Harb Symp Quant Biol 54: 597-603.
  157. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, van der Eb AJ, Melief CJ. 1989. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59: 603-14.
  158. Offringa R, Smits AM, Houweling A, Bos JL, van der Eb AJ. 1988. Similar effects of adenovirus E1A and glucocorticoid hormones on the expression of the metalloprotease stromelysin. Nucleic Acids Res 16: 10973-84.

to top